Zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed Chronic Lymphocytic Leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities

INN:

Subtype:

Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

License:

FDA

Class:

PI3K inhibitors

R/R

PI: http://www.gilead.com/~/media/files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf?la=en 

1. Approved Labelling

Zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed Chronic Lymphocytic Leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

2.  Treatment Regimen

The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily. Zydelig can be taken with or without food. Tablets should be swallowed whole. Continue treatment until disease progression or unacceptable toxicity. The optimal and safe dosing regimen for patients who receive treatment longer than several months is unknown.

3. AE/Warnings

Please see section 5 of the PI.

Disclaimer: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.